Affiliations: [a] Department of Biomedical Sciences, Computational Neurology, Experimental Neurobiology Unit (ENU), University of Antwerp, Belgium
| [b] Department of Neurology, Antwerp University Hospital, Belgium
| [c] Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
Correspondence:
[*]
Correspondence to: Rose Bruffaerts, Computational Neurology, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Belgium. Tel.: +3232653620; E-mail: rose.bruffaerts@uantwerpen.be.
Abstract: Although neuropsychiatric symptoms are a hallmark of the behavioral variant of frontotemporal degeneration (FTD), there is limited evidence on the optimal therapeutic management of these symptoms. In this issue, Katisko et al. report real-world multicentric data on the use of psychopharmacological medication in newly diagnosed patients with FTD. Such reports contribute to knowledge sharing between clinicians caring for patients with FTD. Here, we outline how improved collection of clinical data can assure more robust evidence for future therapies in FTD and other rare neurological diseases.
